HFM NEWS

FEATURED NEWS

All
Update on Recall of Bayer Kogenate FS from National Organizations

Update on Recall of Bayer Kogenate FS from National Organizations

August 1, 2019

Patient organizations are in ongoing communication with manufacturer

National Joint Statement on Recall of Bayer Kogenate FS Lots

National Joint Statement on Recall of Bayer Kogenate FS Lots

August 1, 2019

Last week, Bayer announced the recall of two lots of Kogenate® FS …

<font color=APR 3-5, 2020

SpringFest">

APR 3-5, 2020

SpringFest

July 24, 2019

Save the date! SpringFest is heading to the west side in 2020.Registration …

  • All
  • Advocacy
  • Camp
  • Featured News
  • Medical Advisory
Medical Advisory

Update on Recall of Bayer Kogenate FS from National Organizations

Patient organizations are in ongoing communication with manufacturer

Read More →
Medical Advisory

National Joint Statement on Recall of Bayer Kogenate FS Lots

Last week, Bayer announced the recall of two lots of Kogenate® FS antihemophilic factor (recombinant) 2000 IU vials. That highly concerning announcement has raised many questions on the part of both national organizations and community members.

Read More →
Featured News

Medical Advisory: Bayer Announces Recall of Two Lots of Kogenate FS

July 19, 2019 Bayer has announced a recall of two lots of Kogenate® FS 2000 IU vials.

Read More →
Featured News

Educating, Equipping, and Empowering Women with Hemophilia

Shellye Horowitz reviews the birth of HFM’s National Conference for Women with Hemophilia and the movement to ensure women with hemophilia receive proper medical care.

Read More →
Featured News

Ending Period Poverty

Oscar winning documentary shines light on a cause close to the bleeding disorders community.

Read More →
Camp

Worried About Your Child Getting Homesick?

Planning to send your child to camp this summer? Learn a few tips to help you child overcome feeling homesick from one of camp’s HTC social workers.

Read More →
Advocacy

How Will the Midterm Election Results Affect Healthcare in Michigan?

As the 2019 legislative cycle begins, HFM will be monitoring the introduction of bills and assessing their possible impact on the bleeding disorders community

Read More →
Advocacy

Michigan Passes Medicaid Work Requirements Bill

The bill also includes exemptions for disability caretakers, parents of children under six, pregnant women, people receiving disability benefits, and those who are medically frail, which includes patients diagnosed with hemophilia, VWD, and other factor deficiencies.

Read More →
Advocacy

Children’s Special Health Care Services: Maintaining Access to Care for the Bleeding Disorders Community

CSHCS covers people under the age of 21 with a qualifying medical condition. However, the age limitation is waived for patients with certain blood clotting disorders (hemophilia and other bleeding disorders) and cystic fibrosis.

Read More →
Advocacy

Patient Advocacy Groups Work to Reduce the Impact of Out-of-Pocket Expenses

This legislation would require insurance plans to offer a copay only option, which would not require patients to reach a deductible before their insurance begins to pay a portion of the cost.

Read More →
Advocacy

What is an Accumulator Adjustment Program?

Beginning January 2018, a few health plans, specifically high deductible plans offered by self-insured employer groups, have changed the way they calculate copays for patients using these cards.

Read More →
Advocacy

It’s a Great Time to Review Your Insurance Plan for 2019

A few things to keep in mind! Do you depend on factor co-pay assistance? If so, you should know that some insurance plans have changed …

Read More →
Medical Advisory

CSL Behring Discontinues Production and Distribution of Monoclate-P®

If you are currently using Monoclate-P®, please contact your physician or hemophilia treatment center to learn about other options that are available to you for treatment.

Read More →
Medical Advisory

Genentech Issues Statement on Hemlibra

If you have questions or concerns, please reach out to Genentech and/or your physician.

Read More →
Medical Advisory

Alnylam Suspends Fitusiran Dosing due to Thrombotic Event

The Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.

Read More →